论文部分内容阅读
放射免疫显象技术的出现,为肿瘤的诊断、定位、预后和疗效判断以及随访提供了新的手段,是一项很有发展前途的新技术。国外对其研究正方兴未艾,在国内,我们首先报道了分泌AFP肿瘤放射免疫显象。本研究报告I标记抗CEA单克隆抗体在移植人结肠癌裸鼠的体内定位,I标记抗AFP多克隆抗体、抗卵巢癌多克隆抗体和抗CEA单克隆抗体的临床应用。
The emergence of radioimmunoimaging technology provides a new means for tumor diagnosis, localization, prognosis and curative effect judgment and follow-up. It is a promising new technology. Research abroad is in the ascendant. In China, we first reported the secretion of AFP tumor radioimmunoimaging. This study reports the clinical application of I-labeled anti-CEA monoclonal antibody in vivo in human colon cancer xenografts, I-labeled anti-AFP polyclonal antibody, anti-ovarian cancer polyclonal antibody and anti-CEA monoclonal antibody.